The global c-reactive protein testing market size is expected to be worth around US$ 10.6 billion by 2030, according to a new report by Vision Research Reports.
The global c-reactive protein testing market size was valued at US$ 8.5 billion in 2020 and is anticipated to grow at a CAGR of 0.6% during forecast period 2021 to 2030.
Get Sample Copy of This Report (Including TOC, List of Tables & Figures, and Chart)@ https://www.visionresearchreports.com/report/sample/38686
C-reactive Protein Testing Market (By Assay Type: Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others; By Detection Range: hs-CRP, Conventional CRP, cCRP; By Disease Area: Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others; By End-use: Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home) – Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 – 2030
Report Coverage
| Report Scope | Details |
| Market Size | USD 10.6 billion by 2030 |
| Growth Rate | CAGR of 0.6% From 2021 to 2030 |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Assay type, Detection range, Disease type, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Thermo Fisher Scientific, Inc.; F. Hoffmann-La Roche Ltd; Danaher; Quest Diagnostics; Siemens Healthineers AG; Abbott; Merck KGaAA; Zoetis; Ortho Clinical Diagnostics; Getein Biotech, Inc; HORIBA, Ltd; Randox Laboratories Ltd; BODITECH MED, INC.; Aidian |
Growth Factors
The market growth can be attributed to substantial research activities to explore the applications of C-reactive protein (CRP) testing coupled with the presence of private as well as public agencies which grant funds to expedite the research proceedings in this arena.
A rise in the number of strategic deals and developments coupled with the increase in investments for R&D of C-reactive protein testing is expected to drive the market significantly. The ongoing COVID-19 pandemic has affected the CRP testing market to a great extent. As CRP is considered to be the determining biomarker for the severity of infection/inflammation, the market is witnessing increased demand for CRP testing services and products. Major operating companies such as Abbott offer supportive tools for CRP testing for SARS-CoV-2 infection.
By Assay Type Analysis
The immunoturbidimetric assays dominated the market and accounted for the largest revenue share of 48.5% in 2020. The segment is anticipated to further grow during the forecast period.
Technological advancements in immunoturbidimetric assays are expected to fuel market growth in the coming years. Researchers across the world are actively involved in the development of advanced and innovative assays to support rapid and accurate CRP testing.
By Detection Range Analysis
The hs-CRP segment dominated the CRP testing market and accounted for the largest revenue share of 42.8% in 2020. The segment is anticipated to witness a CAGR of 0.3% from 2021 – 2028.
American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC), hs-CRP acts as an independent marker that facilitates in the estimation of cardiovascular disorders such as myocardial infarction.
By Disease Type Analysis
The Cardiovascular diseases (CVD) segment lead the market and accounted for the largest revenue share of 22.8% in 2020. An increase in the prevalence of CVDs is the major factor contributing to the growth of the market. Adoption of a sedentary lifestyle, obesity, hypertension, and diabetes are few risk factors associated with CVDs.
The cancer segment held the second-largest revenue share in 2020. It is a crucial public health burden across the globe. According to the WHO, there are more than 1.9 million deaths and 3.7 million new cancer cases every year in the European region, hence, there is a need for large-scale adoption of POC CRP testing solutions to aid in the management of cancer in developed and developing countries across the globe.
By End-use Analysis
The hospitals segment dominated the market and lead for the largest revenue share of 31.2% in 2020. The growth of the hospitals segment can be attributed to the rising penetration of CRP testing in hospitals, especially in developing regions across the world.
The clinics segment held a substantial market share throughout the analysis period. CRP testing technology has expanded in the past few years with noteworthy developments in areas of point-of-care and hs-CRP.
By Regional Analysis
North America dominated the C-reactive protein testing market and accounted for the highest revenue share of 40.5% in 2020. Increasing adoption of innovative, advanced technology and high focus on clinical research in North America are among the factors driving the market.
According to the American Cancer Society, prostate cancer is the second most diagnosed cancer in the U.S. and the third leading cause of death in men. Estimates from the same source also indicated that one in 41 men in the U.S. will die as a result of prostate cancer.
Key Players
Market Segmentation
Buy This Premium Research Report, click here@ https://www.visionresearchreports.com/report/cart/38686 or call: +1 9197 992 333
Vision Research Report, Recently Announced New Report on "Smart Lock market - Global Industry Analysis,…
Vision Research Report, Recently Announced New Report on "2D barcode reader market - Global Industry…
Vision Research Report, Recently Announced New Report on "commercial refrigeration equipment market - Global Industry…
Vision Research Report, Recently Announced New Report on "Restaurant Point-of-Sale Terminal market - Global Industry…
Vision Research Report, Recently Announced New Report on "vacuum cleaner market- Global Industry Analysis, Market…
Vision Research Report, Recently Announced New Report on "household refrigerators and freezers market - Global…